Hyperprogression during immunotherapy: do we really want to know?

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

(2019) C G Kim et al.   ANNALS OF ONCOLOGY

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors

(2018) Marjorie Faure et al.   Frontiers in Immunology

Blockade of Tumor-Expressed PD-1 promotes lung cancer growth

(2018) Shisuo Du et al.   OncoImmunology

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

(2018) Roberto Ferrara et al.   JAMA Oncology

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

(2018) Laure Hirsch et al.   BRITISH JOURNAL OF CANCER

Hyperprogressive disease: recognizing a novel pattern to improve patient management

(2018) Stéphane Champiat et al.   Nature Reviews Clinical Oncology

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis

(2017) Tim Wartewig et al.   NATURE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE